Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09
jRCT2031210130Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of trastuzumab deruxtecan, pertuzumab, trastuzumab, docetaxel and paclitaxel in HER2-positive breast cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-free survival by blinded independent central review. Started Aug 2021; status: active, not recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on jRCT2031210130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210130.